Buchumschlag

Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor

Purpose: This study aimed to evaluate a modified EPclin test (mEPclin), a combination of EndoPredict (EP) score, post-neoadjuvant pathologic tumor size and nodal status, for predicting the risk of distance recurrence after neoadjuvant chemotherapy (NACT) in patients with residual estrogen receptor (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Loibl, Sibylle (VerfasserIn) , Weber, Karsten (VerfasserIn) , Huober, Jens (VerfasserIn) , Krappmann, Kristin (VerfasserIn) , Marmé, Frederik (VerfasserIn) , Schem, Christian (VerfasserIn) , Engels, Knut (VerfasserIn) , Pfitzner, Berit Maria (VerfasserIn) , Kümmel, Sherko (VerfasserIn) , Furlanetto, Jenny (VerfasserIn) , Hartmann, Arndt (VerfasserIn) , Darb-Esfahani, Silvia (VerfasserIn) , Müller, Volkmar (VerfasserIn) , Staebler, Annette (VerfasserIn) , Minckwitz, Gunter von (VerfasserIn) , Kronenwett, Ralf (VerfasserIn) , Denkert, Carsten (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: April 4, 2018
In: Clinical cancer research
Year: 2018, Jahrgang: 24, Heft: 14, Pages: 3358-3365
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-17-2947
Online-Zugang:Verlag, Volltext: https://doi.org/10.1158/1078-0432.CCR-17-2947
Verlag: https://clincancerres.aacrjournals.org/content/24/14/3358
Volltext
Verfasserangaben:Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, and Carsten Denkert
Beschreibung
Zusammenfassung:Purpose: This study aimed to evaluate a modified EPclin test (mEPclin), a combination of EndoPredict (EP) score, post-neoadjuvant pathologic tumor size and nodal status, for predicting the risk of distance recurrence after neoadjuvant chemotherapy (NACT) in patients with residual estrogen receptor (ER)-positive/HER2-negative breast cancer. We also compared the prognostic power of the mEPclin with that of the CPS-EG score. - Experimental Design: A total of 428 formalin-fixed, paraffin-embedded tumor samples from GeparTrio and GeparQuattro studies were evaluated for mRNA expression of eight cancer-related and three reference genes. The mEPclin score was computed using a modified algorithm and predefined cut-off values were used to classify each patient at low or high risk. Primary endpoint was disease-free survival (DFS). - Results: A higher continuous mEPclin score was significantly associated with increased risk of relapse [HR, 2.16; 95% confidence interval (CI), 1.86-2.51; P < 0.001] and death (HR, 2.28; 95% CI, 1.90-2.75; P < 0.001). Similarly, patients classified at high risk by dichotomous mEPclin showed significantly poorer DFS and overall survival compared with those at low risk. In contrast with CPS-EG, the mEPclin remained significantly prognostic for DFS in multivariate analysis (HR, 2.13; 95% CI, 1.73-2.63; P < 0.001). Combining CPS-EG and other clinicopathological variables with mEPclin yielded a significant improvement of the prognostic power for DFS versus without mEPclin (c-indices: 0.748 vs. 0.660; P < 0.001). - Conclusions: The mEPclin score independently predicted the risk of distance recurrence and provided additional prognostic information to the CPS-EG score to assess more accurately the prognosis after NACT in the luminal non-pCR patient population. Therefore, this approach can be used to select patients for additional post-neoadjuvant therapies. Clin Cancer Res; 24(14); 3358-65. ©2018 AACR.
Beschreibung:Gesehen am 27.02.2020
Beschreibung:Online Resource
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-17-2947

Ähnliche Einträge